Malin Källsten

Dr. Malin Källsten


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 September 2018 in The Analyst
Verified
Journal Article
Open access
PDF file
MKMalin Källsten
Malin Källsten
RHRafael Hartmann
Rafael Hartmann
KAKonstantin Artemenko
Konstantin Artemenko
SLSara Bergström Lind
Sara Bergström Lind
FLFredrik Lehmann
Fredrik Lehmann
JBJonas Bergquist
Jonas Bergquist
Four different cysteine linked antibody-drug conjugates (ADCs) consisting of Trastuzumab-vc-MMAE were analysed with four common analytical techniques with respect to drug-to-antibody ratio (DAR) and molecular weight.

8 March 2019 in Analytical and Bioanalytical Chemistry
Verified
Journal Article
Open access
PDF file
MKMalin Källsten
Malin Källsten
MPMatthijs Pijnappel
Matthijs Pijnappel
RHRafael Hartmann
Rafael Hartmann
FLFredrik Lehmann
Fredrik Lehmann
LKLucia Kovac
Lucia Kovac
JBJonas Bergquist
Jonas Bergquist
Antibody–drug conjugates (ADCs) are an inherently heterogeneous class of biotherapeutics, the development of which requires extensive characterization throughout. During the earliest phases of preclinical development, when synthetic routes towards the desired conjugate are being assessed, the main interest lies in the determination of the average drug-to-antibody ratio (DAR) of a given batch as well as information about different conjugation species. There has been a trend in mass spectrometry (MS)–based characterization of ADCs towards the use of high-resolving mass spectrometry for many of these analyses. Considering the high cost for such an instrument, the evaluation of cheaper and more accessible alternatives is highly motivated. We have therefore tested the applicability of a quadrupole mass analyzer for the aforementioned characterizations. Eight ADCs consisting of trastuzumab and varying stoichiometries of Mc-Val-Cit-PABC-monomethyl auristatin E conjugated to native cysteines were synthesized and served as test analytes. The average DAR value and molecular weights (Mw) of all detected chains from the quadrupole mass analyzer showed surprisingly high agreement with results obtained from a time-of-flight (TOF) mass analyzer and hydrophobic interaction chromatography (HIC)–derived values for all investigated ADC batches. Acquired Mw were within 80 ppm of TOF-derived values, and DAR was on average within 0.32 DAR units of HIC-derived values. Quadrupole mass spectrometers therefore represent a viable alternative for the characterization of ADC in early-stage development.

8 September 2020 in Antibodies
Verified
Journal Article
Open access
PDF file
MKMalin Källsten
Malin Källsten
RHRafael Hartmann
Rafael Hartmann
LKLucia Kovac
Lucia Kovac
FLFredrik Lehmann
Fredrik Lehmann
SLSara Bergström Lind
Sara Bergström Lind
JBJonas Bergquist
Jonas Bergquist
Antibody–drug conjugates (ADCs) are heterogeneous biotherapeutics and differ vastly in their physicochemical properties depending on their design. The number of small drug molecules covalently attached to each antibody molecule is commonly referred to as the drug-to-antibody ratio (DAR). Established analytical protocols for mass spectrometry (MS)-investigation of antibodies and ADCs often require sample treatment such as desalting or interchain disulfide bond reduction prior to analysis. Herein, the impact of the desalting and reduction steps—as well as the sample concentration and elapsed time between synthesis and analysis of DAR-values (as acquired by reversed phase liquid chromatography MS (RPLC–MS))—was investigated. It was found that the apparent DAR-values could fluctuate by up to 0.6 DAR units due to changes in the sample preparation workflow. For methods involving disulfide reduction by means of dithiothreitol (DTT), an acidic quench is recommended in order to increase DAR reliability. Furthermore, the addition of a desalting step was shown to benefit the ionization efficiencies in RPLC–MS. Finally, in the case of delayed analyses, samples can be stored at four degrees Celsius for up to one week but are better stored at −20 °C for longer periods of time. In conclusion, the results demonstrate that commonly used sample preparation procedures and storage conditions themselves may impact MS-derived DAR-values, which should be taken into account when evaluating analytical procedures.